BML Capital Management, LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
BML Capital Management, LLC disclosed 23 US equity positions worth $130.5m in its Q2 2025 13F filing. The largest position was AVIR at 21.0% of the reported book, followed by THIRD HARMONIC BIO INC and ACRS. Against the Q1 2025 filing, it opened 1 new position, added to 10 and reduced 2 among the top 23 holdings.
What did BML Capital Management, LLC own in Q2 2025? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 21.0% | $27.4m | 7,609,812 | 0% | held |
| 2 | THIRD HARMONIC BIO INC | 15.9% | $20.8m | 3,824,417 | 0% | held | |
| 3 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 15.5% | $20.2m | 14,250,000 | 0% | held |
| 4 | TIL INSTIL BIO INC | 8.5% | $11.1m | 534,899 | 28% | added | |
| 5 | EPIEUR ESSA PHARMA INC | 5.5% | $7.2m | 4,221,546 | 0% | held | |
| 6 | ORMP ORAMED PHARMACEUTICALS INC | 5.3% | $6.9m | 3,083,253 | 2% | added | |
| 7 | AVU0 ADVERUM BIOTECHNOLOGIES INC | 5.0% | $6.6m | 3,057,526 | 11% | added | |
| 8 | IKENA ONCOLOGY INC | 4.1% | $5.4m | 4,030,102 | 9% | added | |
| 9 | PMVP PMV PHARMACEUTICALS INC | 4.1% | $5.3m | 5,000,000 | 33% | added | |
| 10 | ALMS ALUMIS INC | 2.8% | $3.6m | 1,210,415 | 2339% | added | |
| 11 | 2KZ0 KEZAR LIFE SCIENCES INC | 2.2% | $2.9m | 635,183 | 56% | added | |
| 12 | LAVA THERAPEUTICS NV | 2.0% | $2.6m | 1,970,610 | 1% | added | |
| 13 | MIST MILESTONE PHARMACEUTICALS IN | 1.7% | $2.2m | 1,136,091 | 0% | held | |
| 14 | ELEVATION ONCOLOGY INC | 1.7% | $2.2m | 5,890,434 | -0% | held | |
| 15 | CNTB CONNECT BIOPHARMA HLDGS LTD | 1.4% | $1.8m | 1,821,558 | -13% | reduced | |
| 16 | ASTROTECH CORP | 1.0% | $1.3m | 220,410 | 0% | held | |
| 17 | ATHIRA PHARMA INC | 0.7% | $975.7k | 3,230,667 | 1% | added | |
| 18 | LSTA LISATA THERAPEUTICS INC | 0.5% | $608.3k | 209,814 | -3% | reduced | |
| 19 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.4% | $475.1k | 118,766 | – | new |
| 20 | TURNSTONE BIOLOGICS CORP | 0.3% | $396.1k | 1,103,386 | 0% | held | |
| 21 | VTGN VISTAGEN THERAPEUTICS INC | 0.2% | $300.0k | 150,000 | 0% | held | |
| 22 | HILLEVAX INC | 0.1% | $182.9k | 91,913 | 343% | added | |
| 23 | VRCA VERRICA PHARMACEUTICALS INC | 0.1% | $92.6k | 174,651 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.